Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

The Effects of GIP and GLP-2 on the Secretion of Glucagon in Patients With Type 1 Diabetes

This study has been completed.
University of Copenhagen
Information provided by:
University Hospital, Gentofte, Copenhagen Identifier:
First received: August 11, 2008
Last updated: February 12, 2009
Last verified: February 2009
The purpose of this study is to determine whether Glucose-dependent Insulinotropic Polypeptide (GIP) or Glucagon Like Peptide 2 (GLP-2) has an affect on the secretion of Glucagon from the pancreas in patients with type 1 diabetes mellitus.

Condition Intervention
Diabetes Mellitus
Other: GIP-infusion
Other: Sodium-chloride
Other: GLP-2 infusion

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Single Blind (Participant)
Primary Purpose: Basic Science
Official Title: The Effects of GIP and GLP-2 on the Secretion of Glucagon in Patients With Type 1 Diabetes

Resource links provided by NLM:

Further study details as provided by University Hospital, Gentofte, Copenhagen:

Primary Outcome Measures:
  • plasma-glucagon Area Under Curve at 0-90 min. and 90-180 min.

Enrollment: 8
Study Start Date: January 2008
Primary Completion Date: August 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: B
GLP-2 infusion
Other: GLP-2 infusion
Placebo Comparator: C
Sodium-chloride infusion
Other: Sodium-chloride
Active Comparator: A
Other: GIP-infusion


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Caucasians over 18 years with type 1 diabetes (WHO criteria)
  • Arginine test without rise in plasma C-peptide
  • Normal blood Hemoglobin
  • Informed consent

Exclusion Criteria:

  • Liver disease
  • Diabetic nephropathy
  • Treatment with medications unpausable for 12 hours
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00732602

University Hospital, Gentofte
Hellerup, Capital Region, Denmark, 2900
Sponsors and Collaborators
University Hospital, Gentofte, Copenhagen
University of Copenhagen
  More Information

Responsible Party: Mikkel Christensen MD, University Hospital, Gentofte, Copenhagen Identifier: NCT00732602     History of Changes
Other Study ID Numbers: H-D-2007-0058
Study First Received: August 11, 2008
Last Updated: February 12, 2009

Keywords provided by University Hospital, Gentofte, Copenhagen:
Glucose-dependent Insulinotropic Polypeptide
Glucagon-Like peptide 2

Additional relevant MeSH terms:
Diabetes Mellitus
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Gastric Inhibitory Polypeptide
Glucagon-Like Peptide 1
Gastrointestinal Agents
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Incretins processed this record on April 27, 2017